Insilico Medicine Secures Nearly $120M AI-Driven Cardiometabolic Drug Deal with Qilu Pharmaceutical
Insilico Medicine and Qilu Pharmaceutical announced a collaboration valued at nearly $120 million to develop small molecule therapies for cardiometabolic diseases such as obesity, Type 2 diabetes, and heart failure.234
Insilico will use its Pharma.AI platform to design and optimize novel small molecules against undisclosed targets, while Qilu handles further development, regulatory activities, and commercialization.3467
The deal includes development and commercialization milestone payments plus single-digit royalties on net sales; upfront fee not disclosed.346
This expands a prior relationship from 2021 when Qilu licensed Insilico's PandaOmics software, following Insilico's November 2025 unveiling of its cardiometabolic portfolio.48
News reported around January 27, 2026, aligning with Insilico's strategy post its December 2025 Hong Kong IPO.34
Sources:
2. https://www.thailand-business-news.com/pr-news/insilico-medicine-and-qilu-pharmaceutical-reach-near-120-million-drug-development-collaboration-to-accelerate-novel-cardiometabolic-therapies
3. https://www.fiercebiotech.com/biotech/qilu-programs-path-cardiometabolic-disease-120m-ai-enabled-insilico-alliance
4. https://www.biopharmatrend.com/news/in-another-major-rd-deal-insilico-taps-chinese-pharma-for-ai-designed-cardiometabolic-drugs-1480/
6. https://www.pharmajournalist.com/amp/insilico-and-qilu-forge-ai-driven-cardiometabolic-drug-partnership/
7. https://insilico.com/news/ckvxca1tu1-insilico-medicine-and-qilu-pharmaceutica